ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Louisiana » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in Louisiana

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
JON LELEUX MD

Cardiovascular Disease

34,839

$1.76M

1637
1428 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

1%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 27%

$51
Average prescription price

Avg: $60

RICHARD ABBEN MD

Cardiovascular Disease

22,276

$1.07M

1323
1119 are 65+

1%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 27%

$48
Average prescription price

Avg: $60

KENNETH WONG MD

Cardiovascular Disease

21,577

$883K

919
776 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 27%

$41
Average prescription price

Avg: $60

HARRY HAWTHORNE M.D.

Cardiovascular Disease

21,436

$1.23M

1482
1247 are 65+

2%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 27%

$58
Average prescription price

Avg: $60

MICHAEL DIBBS M.D.

Cardiovascular Disease

20,750

$836K

859
656 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 27%

$40
Average prescription price

Avg: $60

FORTUNE DUGAN MD

Cardiovascular Disease

18,119

$1.07M

826
754 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 27%

$59
Average prescription price

Avg: $60

WILLIAM LADD MD

Cardiovascular Disease

16,972

$714K

885
734 are 65+

1%
patients receiving schedule two controlled substances

Avg: 0%

1%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 27%

$42
Average prescription price

Avg: $60

ROBERT GREER M.D.

Cardiovascular Disease

15,832

$755K

821
677 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 27%

$48
Average prescription price

Avg: $60

DENZIL MORAES M.D.

Cardiovascular Disease

15,557

$1.01M

969
844 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 27%

$65
Average prescription price

Avg: $60

ERNEST THOMPSON MD

Cardiovascular Disease

15,524

$958K

606
402 are 65+

4%
patients receiving schedule two controlled substances

Avg: 0%

20%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 27%

$62
Average prescription price

Avg: $60

LEON KRAFT M.D.

Cardiovascular Disease

15,273

$833K

895
696 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

34%
prescriptions for brand name drugs

Avg: 27%

$55
Average prescription price

Avg: $60

MARC BERNSTEIN M.D.

Cardiovascular Disease

14,797

$954K

935
757 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 27%

$64
Average prescription price

Avg: $60

JOHN MICKEY MD

Cardiovascular Disease

14,429

$809K

790
702 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 27%

$56
Average prescription price

Avg: $60

MIKE MOUNIR MD

Cardiovascular Disease

14,374

$589K

1012
901 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 27%

$41
Average prescription price

Avg: $60

WADE MAY MD

Cardiovascular Disease

14,329

$636K

1017
832 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

1%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 27%

$44
Average prescription price

Avg: $60

SYED FAZAL-UR-REHMAN M.D.,

Cardiovascular Disease

14,167

$634K

739
562 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 27%

$45
Average prescription price

Avg: $60

EVENS RODNEY MD

Cardiovascular Disease

14,037

$607K

894
677 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

1%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 27%

$43
Average prescription price

Avg: $60

BOYD HELM

Cardiovascular Disease

13,686

$842K

935
796 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

1%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 27%

$62
Average prescription price

Avg: $60

FARHAD ADULI MD

Cardiovascular Disease

13,585

$723K

987
882 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

6%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 27%

$53
Average prescription price

Avg: $60

SAMUEL STAGG M.D.

Cardiovascular Disease

13,581

$759K

617
524 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 27%

$56
Average prescription price

Avg: $60

EMILE BARROW M.D.

Cardiovascular Disease

13,537

$676K

775
714 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 27%

$50
Average prescription price

Avg: $60

ASSAD MOUHAFFEL MD

Cardiovascular Disease

13,224

$731K

870
710 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 27%

$55
Average prescription price

Avg: $60

ALBERT HAMMETT MD

Cardiovascular Disease

13,043

$785K

909
763 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 27%

$60
Average prescription price

Avg: $60

CHARLES WOODARD M.D.

Cardiovascular Disease

12,832

$976K

303
198 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

13%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 27%

$76
Average prescription price

Avg: $60

JOSE MATHEW MD

Cardiovascular Disease

12,794

$1.02M

764
573 are 65+

2%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 27%

$79
Average prescription price

Avg: $60

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank